Login to Your Account



Biosimilars Bandwagon Builds

Baxter, Momenta Ink Potential $470M Partnership for Six FOBs

By Marie Powers
Staff Writer

Wednesday, December 28, 2011
Baxter International Inc. and Momenta Pharmaceuticals Inc. jumped on the biosimilars bandwagon with a global collaboration to develop and commercialize up to six follow-on biologics (FOBs).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription